key: cord-1014252-x64tii2t
authors: Cevik, Muge; Bamford, Connor; Ho, Antonia
title: COVID-19 pandemic – A focused review for clinicians
date: 2020-04-25
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2020.04.023
sha: aa39ec2d3d5a1170b7f04ae53da6c042602ff41e
doc_id: 1014252
cord_uid: x64tii2t

Abstract Background The COVID-19 pandemic caused by SARS-CoV-2 remains a significant issue for global health, economics and society. A wealth of data has been generated since its emergence in December 2019 and it is vital for clinicians to keep up with this data from across the world at a time of uncertainty and constantly evolving guidelines and clinical practice. Objectives Here we provide an update for clinicians on the recent developments about virology, diagnostics, clinical presentation, viral shedding, and treatment options for COVID-19 based on current literature. Sources We considered published peer-reviewed papers and non-peer-reviewed pre-print manuscripts on COVID19 and related aspects with an emphasis on clinical management aspects. Content We describe the virological characteristics of SARS-CoV-2 and clinical course of COVID-19 with an emphasis on diagnostic challenges, duration of viral shedding, severity markers and current treatment options. Implications The key challenge in managing COVID-19 remains the patient density. However, accurate diagnoses as well as early identification and management of high-risk severe cases are important for many clinicians. For improved management of cases, there is a need to understand test probability of serology, qRT-PCR and radiological testing, and the efficacy of available treatment options that could be used in severe cases with a high risk of mortality.

The first cases of atypical pneumonia of unidentified aetiology were reported on December 30, 2019, 57 from Wuhan, China. By January 7, 2020, a novel betacoronavirus, severe acute respiratory syndrome 58 coronavirus (SARS-CoV-2) was identified, while the disease has been named COVID-19. 59 has now been declared a pandemic, affected nearly every country, with over 2.3 million confirmed 60 cases and >160,000 deaths. The initial clinical case series from China largely comprised of 61 hospitalised patients with severe pneumonia. Further data suggested that approximately 80% patients 62 have mild disease, 20% require hospital admission, and approximately 5% require intensive care 63 admission [1] . Mortality rates are higher among people over 60 years and with coexisting conditions; 64 hypertension, diabetes and cardiovascular disease being the most common. Here we provide an haemorrhagic strokes, as well as muscle injury, have also been reported [19] . A third of patients 111 reported taste or olfactory disorders in a small Italian cohort, including anosmia [20] . Other 112 extrapulmonary manifestations include skin and ocular manifestations. An Italian study reported 113 cutaneous manifestations in 20% patients [21] . Lastly, ocular manifestations consistent with 114 conjunctivitis was reported in 32% COVID patients in a Chinese case series [22] .

The estimated mean incubation period is reported as 3-6 days (range 1.3-11.3) [12] . The duration 117 from symptom onset to dyspnoea was 5-6 days [13, 17] On average, disease progresses further 118 requiring hospitalisation at 7-8 days from symptom onset. Patients may initially appear relatively 119 stable, but they often rapidly deteriorate with severe hypoxia [13, 17] . The key feature seen in these 120 cases is acute respiratory distress syndrome (ARDS) [13, 17] 

These findings suggest that patients may continue to shed RNA in various samples for a long period, 212 but this does not equate to infectiousness potential (Table 1) . This supports the current guidance of 7-213 14 days self-isolation from symptom onset. Certain hospitals following a protocol to confirm viral 214 clearance prior to transfer out of dedicated COVID-19 wards, however, this may not be required 

A wealth of data has been generated already on COVID-19 since early January 2020. Nevertheless, 299 key questions remain regarding understanding the population at risk and age groups, proportion of 300 individuals that have had asymptomatic infections and their transmission potential, endemicity and 301 seasonality of COVID-19, and whether stringent physical distancing measures will be effective in countries outside China. The main challenge in managing COVID19 remains the patient density, 303 however, accurate diagnoses as well as early identification and management of high-risk severe cases 304 remains a daily battle for many clinicians. For improved management of cases, there is a need to 305 understand test probability of serology, qRT-PCR and radiological testing, and the efficacy of 306 available treatment options that could be used in severe cases with high risk of mortality. 

SARS-CoV-2 infection in 86 healthcare workers in two 43

Detection of SARS-CoV-2 in Different Types of Clinical 419 Specimens

Novel Coronavirus can be detected in urine, blood, anal 421 swabs and oropharyngeal swabs samples

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of 423 Infected Patients

Viral dynamics in mild and severe cases of COVID-19

Characteristics of pediatric SARS-CoV-2 infection and potential 427 evidence for persistent fecal viral shedding

The reproductive number of COVID-19 is 429 higher compared to SARS coronavirus

Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2

Estimates of the reproduction 434 number for seasonal, pandemic, and zoonotic influenza: a systematic review of the literature

Early dynamics of transmission and control of 437 COVID-19: a mathematical modelling study. The Lancet Infectious Diseases

Incubation period of 2019 novel coronavirus

nCoV) infections among travellers from Wuhan

Epidemiologic characteristics of early cases with 2019 novel coronavirus (2019-nCoV) 442 disease in Korea

Infections in Residents of a Long-Term Care Skilled Nursing Facility -King County

Presymptomatic Transmission of 450

Superspreading SARS events

Middle East respiratory syndrome 455 coronavirus (MERS-CoV) outbreak in South Korea, 2015: epidemiology, characteristics and 456 public health implications

Comparative therapeutic efficacy of remdesivir and 458 combination lopinavir, ritonavir, and interferon beta against MERS-CoV

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with 461

Severe Covid-19

Coronavirus Susceptibility to the Antiviral 66

In vitro inhibition of severe acute 474 respiratory syndrome coronavirus by chloroquine

In Vitro Antiviral Activity and Projection of Optimized Dosing 477 Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome 478

SARS-CoV-2)

A pilot study 481 of hydroxychloroquine in treatment of patients with common coronavirus disease-19 482 (COVID-19)

The potential role of IL-6 in monitoring severe case of 484 coronavirus disease

Use of siltuximab in patients with COVID-19 486 pneumonia requiring ventilatory support

Infectious Diseases Society of America Guidelines on the Treatment and 491 Management of Patients with COVID-19

Effectiveness of convalescent plasma therapy in severe COVID-494 19 patients

Treatment of 5 Critically Ill Patients With COVID-19 With